Rafael Fuentes-Raspall1, Marta Solans2, Aina Roca-Barceló3, Loreto Vilardell4, Montse Puigdemont5, Sonia Del Barco6, Raquel Comas7, Adelaida García-Velasco8, Aurora Astudillo9, Mª Carme Carmona-Garcia10, Rafael Marcos-Gragera11. 1. Radiation Oncology Service, Josep Trueta University Hospital, Catalan Institute of Oncology, Avinguda de França, S/N, 17007 Girona, Spain. Electronic address: Rfuentes@iconcologia.net. 2. CIBER in Epidemiology and Public Health (CIBERESP), University of Girona (UdG), C/ Universitat de Girona 10,17003 Girona, Spain, Spain; Research Group on Statistics, Econometrics and Health (GRECS), University of Girona (UdG), C/ Universitat de Girona 10,17003 Girona, Spain; Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Carrer del Sol, 15, 17004 Girona, Spain. Electronic address: martasolans@gmail.com. 3. Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Carrer del Sol, 15, 17004 Girona, Spain. Electronic address: ainarb16@gmail.com. 4. Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Carrer del Sol, 15, 17004 Girona, Spain. Electronic address: mlvilardell@iconcologia.net. 5. Hospital Cancer Registry, Josep Trueta University Hospital, Catalan Institute of Oncology, Av de França, 17007, Girona, Spain; Nursing Department, University of Girona, Av de França, 17007, Girona, Spain. Electronic address: mpuigdemont@iconcologia.net. 6. Medical Oncology Service, Josep Trueta University Hospital, Catalan Institute of Oncology, Av de França, 17007, Girona, Spain. Electronic address: Sdel@iconcologia.net. 7. Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Carrer del Sol, 15, 17004 Girona, Spain. Electronic address: raquelcomas14@gmail.com. 8. Medical Oncology Service, Josep Trueta University Hospital, Catalan Institute of Oncology, Av de França, 17007, Girona, Spain. Electronic address: Agarcia2@iconcologia.net. 9. Department of Pathology, Central University Hospital of Asturias (HUCA), Av. de Roma, 33006 Oviedo, Spain. Electronic address: astudillo@hca.es. 10. Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Carrer del Sol, 15, 17004 Girona, Spain; Emergency Department, Josep Trueta University Hospital, Catalan Institute of Oncology, Av de França, 17007, Girona, Spain. Electronic address: mccarmonagarcia22@gmail.com. 11. Research Group on Statistics, Econometrics and Health (GRECS), University of Girona (UdG), C/ Universitat de Girona 10,17003 Girona, Spain; Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Carrer del Sol, 15, 17004 Girona, Spain. Electronic address: rmarcos@iconcologia.net.
Abstract
BACKGROUND: Systematic registration of non-malignant central nervous system (CNS) tumors is a rare practice among European cancer registries. Thus, the real burden of all CNS tumors across Europe is underestimated. The Girona Cancer Registry provides here the first data on CNS tumor incidence and survival trends in Spain for all histological types, including malignant and non-malignant tumors. METHODS: Data on all incident cases of primary CNS tumors notified to the Girona population-based cancer registry from 1994 to 2013 (n=2,131) were reviewed. Incidences rates (IRs) were standardized to the 2013 European population and annual percentage changes (EAPC) were estimated using a piecewise log linear model. 1- and 5-year observed (OS) and relative survival (RS) were also calculated. Results were expressed by sex, age-group, histological subtype and behavior. RESULTS: The overall IR was 16.85 and increased across the period of study (EAPC=+2.2%). The proportion and IRs of malignant (50.2%; IR=9.35) and non-malignant cases (49.8%; IR=9.14) were similar; however, non-malignant tumors were more frequent in women (sex ratio=0.63). The most frequently reported histologies were meningioma (27.6%; IR=5.11) and glioblastoma (22.2%; IR=4.15), which also accounted for the highest and lowest 5-year RS (80.2%; 3.7%, respectively). Globally, 5-year RS was lower in men (42.6% vs. 58.3%, respectively) and in the elderly (64.9% for 0-14years vs. 23.0% for >74years). CONCLUSION: This study presents a comprehensive overview of the epidemiology of malignant and non-malignant CNS primary tumors from the well-established region-wide Girona Cancer Registry (1994-2013). Incidence rates were recovered for all histologies. Survival is still dramatically associated to both age and histological subtype.
BACKGROUND: Systematic registration of non-malignant central nervous system (CNS) tumors is a rare practice among European cancer registries. Thus, the real burden of all CNS tumors across Europe is underestimated. The Girona Cancer Registry provides here the first data on CNS tumor incidence and survival trends in Spain for all histological types, including malignant and non-malignant tumors. METHODS: Data on all incident cases of primary CNS tumors notified to the Girona population-based cancer registry from 1994 to 2013 (n=2,131) were reviewed. Incidences rates (IRs) were standardized to the 2013 European population and annual percentage changes (EAPC) were estimated using a piecewise log linear model. 1- and 5-year observed (OS) and relative survival (RS) were also calculated. Results were expressed by sex, age-group, histological subtype and behavior. RESULTS: The overall IR was 16.85 and increased across the period of study (EAPC=+2.2%). The proportion and IRs of malignant (50.2%; IR=9.35) and non-malignant cases (49.8%; IR=9.14) were similar; however, non-malignant tumors were more frequent in women (sex ratio=0.63). The most frequently reported histologies were meningioma (27.6%; IR=5.11) and glioblastoma (22.2%; IR=4.15), which also accounted for the highest and lowest 5-year RS (80.2%; 3.7%, respectively). Globally, 5-year RS was lower in men (42.6% vs. 58.3%, respectively) and in the elderly (64.9% for 0-14years vs. 23.0% for >74years). CONCLUSION: This study presents a comprehensive overview of the epidemiology of malignant and non-malignant CNS primary tumors from the well-established region-wide Girona Cancer Registry (1994-2013). Incidence rates were recovered for all histologies. Survival is still dramatically associated to both age and histological subtype.
Authors: Amir Salimi; Alireza Zali; Amir Saeid Seddighi; Afsoun Seddighi; Shakila Meshkat; Morteza Hosseini; Amir Nikouei; Mohammad Esmaeil Akbari Journal: J Cancer Epidemiol Date: 2020-09-18
Authors: Fabio Girardi; Brian Rous; Charles A Stiller; Gemma Gatta; Naomi Fersht; Hans H Storm; Jessica R Rodrigues; Christian Herrmann; Rafael Marcos-Gragera; Rafael Peris-Bonet; Mikhail Valkov; Hannah K Weir; Ryan R Woods; Hui You; Patricia A Cueva; Prithwish De; Veronica Di Carlo; Tom Børge Johannesen; Carlos A Lima; Charles F Lynch; Michel P Coleman; Claudia Allemani Journal: Neuro Oncol Date: 2021-10-01 Impact factor: 13.029
Authors: George S Stoyanov; Jonathan S Sarraf; Boyko K Matev; Deyan L Dzhenkov; Martina Kitanova; Bogomil Iliev; Peter Ghenev; Anton B Tonchev; Yavor Enchev; Fernando Adami; Luis Eduardo W De Carvalho Journal: Cureus Date: 2018-02-19
Authors: Stanisław Krajewski; Magdalena Wójcik; Marek Harat; Jacek Furtak Journal: Int J Environ Res Public Health Date: 2021-06-12 Impact factor: 3.390